Amgen And Bioeq Shuttle Stelara Biosimilars Into Phase III Trials
Amgen Study Involves FDA-Approved Product
Almost in tandem, Amgen and Bioeq, with partner Formycon, have advanced their biosimilar Stelara (ustekinumab) candidates into Phase III clinical trials. Both sponsors are aiming to wrap their studies up in 2022.
You may also be interested in...
Amgen has once again touched on its impending expansion into US inflammation/immunology biosimilars, with launches for adalimumab and ustekinumab scheduled for the coming years.
Samsung Bioepis has become the latest firm to move an ustekinumab biosimilar into Phase III trials, with the firm’s SB17 proposed Stelara rival kicking off a study in plaque psoriasis patients.
Bio-Thera has joined the ranks of biosimilars developers that have rivals to Stelara in Phase III trials, after kicking off a study for its BAT2206 proposed version of ustekinumab.